We are international
Donate
TEXT SIZE   


May 7, 2002: IMF Myeloma Minute
05.07.02

What's New at the IMF:

One Voice Against Cancer Advocacy Days, June 3rd & 4th, 2002
Join forces with fellow myeloma patients, their families, friends and the IMF as we come together to lobby for an increased research budget for the National Cancer Institute. Become an advocate for the myeloma community! Every voice counts - make sure your voice is heard.

Make it a Week in Washington -- Extend Your Advocacy Trip to Include the IMF's D.C. Area Patient & Family Seminar!
The International Myeloma Foundation will host a Patient & Family Seminar in the
Washington DC area at the Ritz-Carlton in Tyson's Corners, VA on June 7th and 8th, 2002. IMF Seminars are the best way to stay abreast of the latest developments in the treatment and management of multiple myeloma. They are excellent for both newly-diagnosed patients as well as "myeloma veterans."

IMF to Host Patient & Family Seminar in Chicago, IL
The International Myeloma Foundation will host a summer Patient & Family Seminar August 16th and 17th at the Millennium Knickerbocker Hotel in Chicago, IL. Stay tuned for exciting announcements regarding speakers and presentation topics.


Research Abstracts:

Interleukin-21 is a growth and survival factor for human myeloma cells.

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma.

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

Molecular Targets of Arsenic Trioxide in Malignant Cells.


Myeloma in the News:

Medicare Payment for Cancer Drugs Is Seen as Likely
WASHINGTON, April 28 — Congress appears likely to provide coverage for cancer drugs under Medicare this year, lawmakers and lobbyists say, even as it remains unable to agree on a plan to offer comprehensive drug benefits.

EntreMed Says Panzem Kills Tumor Cells In Preclinical
ROCKVILLE, Md. -(Dow Jones)- EntreMed Inc. (ENMD) said its Panzem drug candidate killed tumor cells and supporting blood vessel cells in a preclinical study to investigate how it inhibits tumor cell growth.

Genta, Aventis Sign Biotech Deal
TRENTON, N.J. (AP) - Genta Inc. has signed a deal worth up to $480 million with European pharmaceutical giant Aventis to jointly finish testing and bring to market Genta's experimental drug Genasense, which appears to help other cancer drugs work better.

Dendreon Gets FDA Orphan Drug Status for Mylovenge
SEATTLE -(Dow Jones)- Dendreon Corp. (DNDN) said its therapeutic vaccine for multiple myeloma, Mylovenge, received orphan drug status by the Food and Drug Administration


Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Please consider showing your support by making a tax-deductible donation today. Donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.


View Back Issues Online...
New to the IMF Myeloma Minute? See what you've been missing by viewing previous issues online!


Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here. You can also view back issues of Myeloma Minute online.


If you no longer wish to receive the Myeloma Minute, please visit the log-in page, enter your email address and name and click the "unsubscribe me" button at the bottom of the page.


 related articles